Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Astellas

Status

Completed

Conditions

Overactive Bladder (OAB)

Treatments

Drug: solifenacin

Drug: mirabegron

Drug: darifenacin

Drug: trospium

Drug: propiverine

Drug: imidafenacin

Drug: fesoterodine

Drug: oxybutynin

Drug: tolterodine

Study type

Observational

Funder types

Industry

Identifiers

NCT03602508

178-MA-3147

Details and patient eligibility

About

The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan.

This study will also assess the persistence to the overall Overactive bladder (OAB) treatments of a patient, regardless of treatment discontinuation or switch to other OAB medications.

Full description

This study is entirely descriptive using secondary medical claim and pharmacy prescription data. No formal comparisons between users of mirabegron and antimuscarinic will be made. Furthermore, no a priori hypothesis testing is intended.

Enrollment

5,589 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient with a new prescription of the index medication within the index period;
Patient received orally administered monotherapy for OAB on index date.

Exclusion criteria

Patient with prior dispensing record of the index medication during the pre-index period;
Patient received onabotulinumtoxin A and/or surgical intervention as part of the OAB treatment between the pre index and post-index period;
Patient diagnosed with stress incontinence (International Classification of Diseases-10 (ICD-10) N39.3 or equivalent) or had dispensing record of medication for stress incontinence (duloxetine) before index date;
Patient with urinary tract infection (ICD-10 N30.0 or equivalent) (for National Health Insurance Research Database (NHIRD) and Health Insurance Review and Assessment (HIRA) database) or a co-prescription of any antibiotics (for NostraData) on index date.

Trial design

5,589 participants in 2 patient groups

mirabegron

Description:

Patients on mirabegron as prescribed by a physician in routine clinical practice.

Treatment: